BioinvestGPT

BioinvestGPT ApS · Research use only

Case study · Zanidatamab

We called the Zanidatamab triplet’s OS benefit, locked 19 Jan 2025, 302 days before the readout

BVCT locked a SUCCESS call on the zanidatamab triplet in HERIZON-GEA-01 (No. 590) on . Jazz Pharmaceuticals reported positive results on , 302 days later; the dashboard classifies the readout as True Positive (TP). Three earlier HER2+ calls (No. 1421, 1307, 1095) are also classified correct.

Ex-ante · timestamped . 302 days before the readout. We called the Zanidatamab triplet’s OS benefit — locked .

Jazz Pharmaceuticals · HERIZON-GEA-01 · NCT05152147 · Phase 3 · Index #590 · audit at data.bioinvestgpt.com

Prior calls · the HER2+ family

We’ve called the HER2+ family before. 4 for 4.

Lead times across the four: 333, 302, 153 and 36 days. Audit each call on the dashboard: #590 · #1421 · #1307 · #1095.

The blind spot

They mine correlations. We simulate causes.

The readout

: moderately superior to SoC. The carousel: HR < 0.8 on OS (the carousel’s wording; the recorded call names no hazard-ratio threshold; OS HR 0.72, published ). Timestamped 302 days early.

Prospective prediction locked on . Confirmed . The dashboard classifies the readout as True Positive (TP). Source: HERIZON-GEA-01 readout (Jazz Pharmaceuticals release) · audit at data.bioinvestgpt.com.

The one point

We know your HR today. You don’t have to wait for the curve. We never access your patient data.

The 3-asset challenge

Name 3 assets keeping you up at night. HRs back in 7 days. Your patient data stays yours.

Clinical foresight. Start at bvct.bioinvestgpt.com. Causal foresight · not statistical hindsight.

The four HER2+ calls on the dashboard

No. 590Correct Prediction

HERIZON-GEA-01 · Zanidatamab

Sponsor
Jazz Pharmaceuticals
Phase
Phase 3
Prediction Date
Readout Date
Prediction To Readout
302 days in advance
Prediction Classification
True Positive (TP)
Technical Prediction
SUCCESS (statistically significant clinical benefit in ORR/PFS for [zanidatamab + tislelizumab + chemotherapy] at least numerically superior to [zanidatamab + chemotherapy]; both superior to [trastuzumab + chemotherapy])
Commercial Prediction
SUCCESS (commercially sufficient clinical benefit in OS for [zanidatamab + tislelizumab + chemotherapy] at least numerically superior to [zanidatamab + chemotherapy]; both superior to [trastuzumab + chemotherapy])
No. 1421Correct Prediction

PATINA · Palbociclib

Sponsor
Pfizer
Phase
Phase 3
Prediction Date
Readout Date
Prediction To Readout
333 days in advance
Prediction Classification
True Positive (TP)
Technical Prediction
partial SUCCESS (statistically significant additive clinical benefit in PFS but not in OS)
Commercial Prediction
partial SUCCESS (commercially sufficient yet limited additive clinical benefit in PFS but not in OS)
No. 1307Correct Prediction

NCT04660929 · CT-0508 Pembrolizumab

Sponsor
Carisma Therapeutics
Phase
Phase 1
Prediction Date
Readout Date
Prediction To Readout
153 days in advance
Prediction Classification
True Negative (TN)
Technical Prediction
FAILURE (statistically insignificant additive clinical benefit)
Commercial Prediction
FAILURE (commercially insufficient additive clinical benefit)
No. 1095Correct Prediction

ASPEN-06 · Evorpacept (ALX148)

Sponsor
ALX Oncology
Phase
Phase 2 Phase 3
Prediction Date
Readout Date
Prediction To Readout
36 days in advance
Prediction Classification
True Positive (TP)
Technical Prediction
SUCCESS (statistically significant additive clinical benefit to trastuzumab + ramucirumab + paclitaxel in ORR as 2L/3L treatments for advanced HER2-overexpressing gastric cancer for phase 2)
Commercial Prediction
SUCCESS (statistically significant additive clinical benefit to trastuzumab + ramucirumab + paclitaxel in OS as 2L/3L treatments for advanced HER2-overexpressing gastric cancer for phase 3)

Start at bvct.bioinvestgpt.com →

All solutionsReturn to the dashboard